Skip to main content

Advertisement

Table 1 Patient demographic and baseline clinical characteristics

From: Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy

  Moderately Emetogenic Chemotherapy Highly Emetogenic Chemotherapy
APF530
250 mg
n = 149
APF530
500 mg
n = 140
Palonosetron
0.25 mg
n = 134
APF530
250 mg
n = 60
APF530
500 mg
n = 67
Palonosetron
0.25 mg
n = 58
Age, mean (SD), y 53.3 (12.05) 54.3 (11.96) 55.0 (11.24) 50.3 (10.83) 49.8 (9.59) 52.6 (12.66)
Female, n (%) 149 (100) 137 (97.9) 132 (98.5) 60 (100) 67 (100) 58 (100)
ECOG PS 0–1, n (%) 145 (97.3) 140 (100) 131 (97.8) 59 (98.3) 65 (97.0) 56 (96.6)
Race/ethnicity, n (%)
 White or Caucasian 80 (53.7) 83 (59.3) 94 (70.1) 17 (28.3) 35 (52.2) 32 (55.2)
 Black or African American 11 (7.4) 15 (10.7) 12 (9.0) 8 (13.3) 3 (4.5) 1 (1.7)
 Hispanic or Latino 12 (8.1) 9 (6.4) 6 (4.5) 6 (10.0) 6 (9.0) 5 (8.6)
 Asian 42 (28.2) 30 (21.4) 22 (16.4) 25 (41.7) 22 (32.8) 20 (34.5)
 Other 4 (2.7) 3 (2.1) 0 4 (6.7) 1(1.5) 0
Hesketh class, n (%)
 1–2 0 0 1 (0.7) 0 0 0
 3 3 (2.0) 6 (4.3) 6 (4.5) 0 0 0
 4 145 (97.3) 131 (93.6) 127 (94.8) 2 (3.3) 3 (4.5) 1 (1.7)
 5 1 (0.7) 3 (2.1) 0 58 (96.7) 64 (95.5) 57 (98.3)
  1. ECOG PS Eastern Cooperative Oncology Group performance status